| Market Cap | 108.58M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -50.39M | Forward P/E | -1.77 | EPS next Y | -1.10% | 50D Avg Chg | -7.00% |
| Sales | 353k | PEG | -0.13 | EPS past 5Y | - | 200D Avg Chg | -9.00% |
| Dividend | N/A | Price/Book | 0.97 | EPS next 5Y | 13.00% | 52W High Chg | -53.00% |
| Recommedations | 2.00 | Quick Ratio | 6.13 | Shares Outstanding | 67.94M | 52W Low Chg | 29.00% |
| Insider Own | 2.62% | ROA | -31.72% | Shares Float | 60.12M | Beta | 1.23 |
| Inst Own | 61.90% | ROE | -62.31% | Shares Shorted/Prior | 383.05K/289.27K | Price | 2.00 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 498,080 | Target Price | 22.60 |
| Oper. Margin | -15,557.79% | Earnings Date | May 7 | Volume | 336,694 | Change | 1.52% |
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
| RBC Capital | Outperform | Mar 15, 24 |
| HC Wainwright & Co. | Buy | Mar 15, 24 |
| HC Wainwright & Co. | Buy | Feb 21, 24 |
| HC Wainwright & Co. | Buy | Sep 21, 23 |
| HC Wainwright & Co. | Buy | Sep 14, 23 |
| HC Wainwright & Co. | Buy | Aug 10, 23 |
| Piper Sandler | Overweight | Jul 21, 23 |
| Oppenheimer | Perform | Jul 5, 23 |
| HC Wainwright & Co. | Buy | May 23, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Broadfoot Jill Marie | Chief Financial Offi.. Chief Financial Officer | Feb 05 | Sell | 1.69 | 1,590 | 2,687 | 20,821 | 02/06/24 |
| SCHIMMEL PAUL | Director Director | May 10 | Buy | 2.25 | 200,000 | 450,000 | 313,023 | 05/11/23 |
| Broadfoot Jill Marie | Chief Financial Offi.. Chief Financial Officer | Feb 03 | Sell | 2.36 | 1,566 | 3,696 | 15,460 | 02/06/23 |
| Shukla Sanjay | President and CEO President and CEO | Nov 21 | Buy | 2.1405 | 10,000 | 21,405 | 50,798 | 11/21/22 |
| Broadfoot Jill Marie | Chief Financial Offi.. Chief Financial Officer | Jan 13 | Buy | 6.75 | 1,923 | 12,980 | 12,112 | 01/18/22 |
| Shukla Sanjay | President and CEO President and CEO | Jan 07 | Buy | 6.7613 | 5,000 | 33,806 | 25,798 | 01/10/22 |